 Eli Lilly And Co NYSE: LLY announced Tuesday a big-ticket acquisition that would mark its foray into gene therapy research. What Happened: Lilly said it has agreed to buy gene therapy company Prevail Therapeutics Inc NASDAQ: PRVL for 22.50 per share in cash payable at closing, and a non-tradable contingent value right, or CVR, worth up to 4 per share in cash. 